Drugs / Adapalene/benzoyl peroxide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02249104 | Aug 2014 → Feb 2015 | acne | Galderma R&D | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-22 | Galderma R&D | Regulatory Galderma receives U.S. FDA approval for Differin® Epiduo® Acne Gel Prescription-to-OTC switch galderma.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-22 | Galderma R&D | Galderma receives U.S. FDA approval for Differin® Epiduo® Acne Gel Prescription-to-OTC switch galderma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adapalene/benzoyl peroxide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02249104 ↗ |
| Route | Topical | “Topical AV therapy” NCT02249104 ↗ |